Autopsy report · NCT00958412
Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study
Cause of deathFunding or business, also safety
“Repros stopped the study for safety and FDA put the study on hold for safety.”
Life of this trial
- Registered 5 months after it had already started.
- Ran for about 6 months before it stopped.
- 18 participants enrolled.
- Results were posted on the registry 9 years 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Repros Therapeutics Inc.
- Sponsor type
- Industry
- Conditions
- Endometriosis
- Interventions
- Proellex®
- Participants
- 18
- Sites
- 8
- Countries
- United States
Trials that died the same way
- Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
“The study was stopped due to safety concerns” - Stroke With Transfusions Changing to Hydroxyurea
“The study has been stopped due to safety and futility concerns.” - Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
“The study stopped due to marketing approval by the FDA.” - Nasal High-frequency Jet Ventilation (nHFJV) Following Extubation in Preterm Infants
“Study stopped due to safety reasons.” - A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis
“FDA requested us to stop the study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.